Antibody Persistence And Long Term Safety Of A Chikungunya Virus Vaccine Candidate (VLA1553)

Condition:   Chikungunya Virus Infection Intervention:   Biological: VLA1553 Sponsor:   Valneva Austria GmbH Enrolling by invitation
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials